Showing results (11-20 of 28) with videos related to
Sort By:
Pageof 3
Clinics in Dermatology|May 19, 2020
Evidence-based best practice advice for patients treated with systemic immunosuppressants in relation to COVID-19Fabrizio Galimberti, Jeffrey McBride, Megan Cronin, et al.Journal of Drugs in Dermatology : JDD|May 6, 2025
Is Upadacitinib Cardioprotective in Chronic Inflammatory Diseases? A Review of Major Adverse Cardiovascular Events and Venous Thromboembolism in Atopic DermatitisOmar Alani, David Wang, Samer Wahood, et al.Brazilian Journal of Anesthesiology (Elsevier)|January 27, 2018
[The influence of the menstrual cycle on acute and persistent pain after laparoscopic cholecystectomy]Sinem Sari, Betul Kozanhan, Ayse Ilksen Egilmez, et al.Journal of Cellular Biochemistry|September 18, 2007
Cyclin degradation for cancer therapy and chemopreventionSarah J Freemantle, Xi Liu, Qing Feng, et al.The Journal of Investigative Dermatology|January 26, 2016
Increased, but Functionally Impaired, CD14(+) HLA-DR(-/low) Myeloid-Derived Suppressor Cells in Psoriasis: A Mechanism of Dysregulated T CellsDavid C Soler, Andrew B Young, Lori Fiessinger, et al.Spine|May 9, 2015
A Systematic Review of Lumbar Fusion Rates With and Without the Use of rhBMP-2Fabrizio Galimberti, Daniel Lubelski, Andrew T Healy, et al.Journal of Drugs in Dermatology : JDD|July 8, 2025
Treating Chronic Hand Eczema with Upadacitinib: Insights from Clinical Trials and Real-World ExperienceOmar Alani, Lara Shqair, Walter J Liszewski, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 24, 2009
Targeting the cyclin E-Cdk-2 complex represses lung cancer growth by triggering anaphase catastropheFabrizio Galimberti, Sarah L Thompson, Xi Liu, et al.Pharmaceuticals (Basel, Switzerland)|June 27, 2025
Fluoroquinolones for Dermatologists: A Practical Guide to Clinical Use and Risk ManagementSamer Wahood, Omar Alani, Iyla Draw, et al.Molecular Cancer Therapeutics|July 4, 2012
Evidence for the ubiquitin protease UBP43 as an antineoplastic targetYongli Guo, Fadzai Chinyengetere, Andrey V Dolinko, et al.Pageof 3